ImmunoGen, Inc. Announces Favorable Update Provided by Roche Related to Its Trastuzumab-DM1 Regul...
There are 1 comment on the Customer Interaction Solutions story from Apr 17, 2010, titled ImmunoGen, Inc. Announces Favorable Update Provided by Roche Related to Its Trastuzumab-DM1 Regul.... In it, Customer Interaction Solutions reports that:
T-DM1 comprises ImmunoGen's DM1 cancer-cell killing agent linked to the HER2-targeting antibody, trastuzumab, developed by Genentech, a wholly owned member of the Roche Group.
Join the discussion below, or Read more at Customer Interaction Solutions.
#1 Apr 18, 2010
Add your comments below
|Roche, ImmunoGen Bullseye Breast-Cancer Drug Wi... (Feb '13)||Feb '13||gdpawel||1|
Find what you want!
Search ImmunoGen Forum Now
Copyright © 2017 Topix LLC